Abstract
Global risk management refers to both a problem in comprehensive therapy as well as a worldwide concern. Seventy years ago the agenda for the first scientific sessions of the American Heart Association (AHA) revealed striking similarities to problems that are of concern today. Only 200 scientists attended those first sessions to hear ten papers presented; at the most recent AHA meeting, nearly 36,000 physicians, researchers, and other health care professionals attended the sessions and more than 3,600 abstracts were presented. Interestingly, the first four presentations in 1925 dealt with 1) “An official method for lessening heart disease”: primary prevention; 2) “The care of adults with moderate heart disorders”: secondary prevention; 3) “The economic aspects of heart disease”; and 4) “What can the American Heart Association Accomplish.” It is possible to take the agenda from the first AHA meeting and apply it to what is now understood to be a contemporary global problem. The issues and problems have not changed in the intervening years. What has changed is the toll of cardiovascular disease, both in the United States and worldwide. For both American men and women, cardiovascular diseases (CVD) are the leading cause of death and mortality, and in women CVD mortality now exceeds that for men [1]. In fact, for the past decade the in the United States more women than men have died from CVD annually. Throughout the world, one sees a staggering mortality from ischemic heart disease and stroke in both the developed and the developing nations. By the year 2020, heart disease is predicted to be the leading cause of total disease burden for the entire world [2]. Thus a virtual CVD epidemic is occurring on a global basis, while the issue and threat of infectious diseases and nutrition are being resolved.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
American Heart Association. Heart and stroke facts: 1996 statistical supplement. Dallas, Texas: American Heart Association, 1996.
Murray CJL, Lopez AD. The global burden of disease. Cambridge, Massachusetts: Harvard University Press, 1996.
Miller DB. Secondary prevention for ischemic heart disease. Arch Intern Med 1997; 157: 2045–52.
Brown MS, Goldstein JL. Heart attacks-Gone with the century? (Editorial). Science 1996; 272: 629.
Ellerbeck EF, Jencks SF, Radford MJ, et al. Quality of care for Medicare patients with acute myocardial infarction: A four-state pilot study from the Cooperative Cardiovascular Project. JAMA 1995; 273: 1509–14.
Cohen MV, Byrne MJ, Levine B, et al. Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation 1991; 83: 1294–1304.
The Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Five-year clinical and functional outcomes comparing bypass surgery and angioplasty in patients with multivessel coronary disease. JAMA 1997; 277: 715–21.
Smith SC Jr., Blair SN, Criqui MH, et al. Preventing heart attack and death in patients with coronary disease. Circulation 1995; 92: 2–4.
Pyrola K, DeBacker G, Graham I, et al. Prevention of coronary heart disease in clinical practice: Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300–31.
Cameron A, Davis K, Rogers W. Recurrence of angina after coronary artery bypass surgery: Predictors and prognosis (CASS Registry). J Am Coll Cardiol 1995; 26: 895–99.
Van Gogh V. Skull with a Burning Cigarette. 1885. Amsterdam, van Gogh Museum.
Lorgeril M, Salen P, Martin JL, et al. Effect of a Mediterranean type of diet on the rate of cardiovascular complications in patients with coronary artery disease. J Am Coll Cardiol 1996; 28: 1103–8.
Sullivan JM. Estrogen replacement. Circulation 1996; 94: 2699–2702.
Hill MN, Houston-Miller N. Compliance enhancement: A call for multidisciplinary team approaches. Circulation 1996; 93: 4–6.
De Busk RF, Houston-Miller N, Superko R, et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann hit Med 1994; 120: 721–29.
Kassirer J. Mergers and acquisitions-who benefits? Who loses? N Engl J Med 1996; 334: 722–23.
Johannesson M, Jonsson B, Kjekshus J, et al. Cost effectiveness of Simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997; 336: 332–36.
Iglehart JK. The National Committee for Quality Assurance. N Engl J Med 1996; 335: 995–99.
Keys A. Coronary heart disease in seven countries. Circulation 1970; 41 (Suppl.I): 1–211.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Smith, S.C. (1998). Global Risk Management: New Strategies for Implementation. In: Gotto, A.M., Lenfant, C., Paoletti, R., Catapano, A.L., Jackson, A.S. (eds) Multiple Risk Factors in Cardiovascular Disease. Medical Science Symposia Series, vol 12. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5022-4_39
Download citation
DOI: https://doi.org/10.1007/978-94-011-5022-4_39
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6108-7
Online ISBN: 978-94-011-5022-4
eBook Packages: Springer Book Archive